Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

5,961 total articles

Nvidia: Ride the AI Demand Wave — A Tactical Long with Defined Risk

Nvidia: Ride the AI Demand Wave — A Tactical Long with Defined Risk

Nvidia (NVDA) remains the central beneficiary of surging AI infrastructure demand. Strong quarterly results, robust free cash flow, expanding addressable market via CPUs and ecosystem partnerships are generating durable pricing and volume tailwinds. Technicals show neutral momentum but volume and short interest dynamics leave room for a sustained m…

Antero Resources: Upgrade to Long - Thesis Centered on a Path to >$1.7B 2026 FCF and Attractive Valuation

Antero Resources: Upgrade to Long - Thesis Centered on a Path to >$1.7B 2026 FCF and Attractive Valuation

Antero Resources looks like a compelling long after recent weakness: solid balance sheet, sub-7x EV/EBITDA, and a path to much higher free cash flow in 2026 in a stronger gas price environment. Our projection models show the company capable of generating north of $1.7 billion in FCF in 2026 under conservative commodity and midstream assumptions. We…

Buy the Dip in Apogee: Positioning for a Zumilokibart-Fueled Re-rate

Buy the Dip in Apogee: Positioning for a Zumilokibart-Fueled Re-rate

Apogee Therapeutics is a clinical-stage biotech with a lead anti-IL-13 program, zumilokibart (APG777), that has shown strong durability in Phase 2 and a runway extended by recent equity raises. The shares pulled back into the low $70s and look like a tactical long for patient traders willing to ride clinical catalysts into late 2026. This trade ide…

Buy TGTX on BRIUMVI Momentum - Actionable Entry at $39.21, Target $54

Buy TGTX on BRIUMVI Momentum - Actionable Entry at $39.21, Target $54

TG Therapeutics is a tactical buy after management signaled a stronger 2026 outlook tied to BRIUMVI expansion and continued commercial execution. The company now sports a roughly $6.0 billion market cap, improving revenue traction, and still-constructive valuation metrics versus growth prospects. This trade lays out entry, stop, and target levels a…

Nebius: Betting on a Pullback After a 684% Revenue Run

Nebius: Betting on a Pullback After a 684% Revenue Run

Nebius reported a 684% revenue surge that has captivated traders. That growth looks real on the top line, but a thin liquidity profile, likely one-time drivers and opaque cash flow dynamics create a measurable downside if earnings quality or cash visibility disappoint. This is a tactical short idea with clearly defined entry, stop and targets over …

Buy the Dip, Brace for the Pain: MercadoLibre for Patient Bulls

Buy the Dip, Brace for the Pain: MercadoLibre for Patient Bulls

MercadoLibre (MELI) is under pressure as management sacrifices margins to defend Latin American market share and scale fintech products. Current weakness creates a tradeable long opportunity: enter near $1690, stop at $1525, target $2400 over a long-term window (180 trading days). Expect volatility in the next 10-45 trading days as investments read…

Microsoft: Expensive vs. History, But Setup for a Mid-Term Upside

Microsoft: Expensive vs. History, But Setup for a Mid-Term Upside

Microsoft ($MSFT) trades well above its 50-day average and at a premium to the market, but fundamentals remain solid: $3.16T market cap, $72.9B free cash flow, 30% ROE, and low leverage. For traders willing to accept limited valuation risk, a controlled long with a $426 entry, $400 stop and $455 target over a mid-term (45 trading days) horizon bala…

Dave Is Positioned to Lead the Next Wave of Fintech Winners

Dave Is Positioned to Lead the Next Wave of Fintech Winners

Dave Inc. looks like a fintech that has graduated from early-stage promise to near-term commercial clarity. With 2025 revenue up roughly 60%, net income of $195.9M, strong free cash flow of $326.5M, and a market cap near $3.4B, Dave is delivering both growth and profitability. This trade plan targets $420 over a 180-trading-day window while protect…

Kohl's Stabilization Looks Real — Tactical Long After Earnings Beat

Kohl's Stabilization Looks Real — Tactical Long After Earnings Beat

Kohl's ($KSS) delivered an earnings beat while management signaled no new store closures and a focus on omnichannel execution. The stock has recovered from its spring lows and now trades on single-digit earnings multiples with a 3.9% yield and positive technical momentum. We upgrade to a tactical long for a mid-term swing (45 trading days) with a c…

Buy Netflix Now: This Is the Bottom the Market Can’t Ignore

Buy Netflix Now: This Is the Bottom the Market Can’t Ignore

Netflix is sitting above a clean technical and fundamental floor after a painful selloff. The business is cash-generative, has strong returns on capital, and recent one-time items that distorted reported EPS are fading. With a market cap near $361B, EV/EBITDA of 9.5 and free cash flow of roughly $11.9B, the risk-reward favors a tactical long: entry…

AMD Upgrade: Play the AI Upside Without Betting on Beating Nvidia

AMD Upgrade: Play the AI Upside Without Betting on Beating Nvidia

AMD is positioned to capture meaningful AI-related revenue growth through EPYC CPUs, GPU accelerators and differentiated system-level wins. We upgrade AMD to a buy and present a concrete trade plan calibrated to a 180-trading-day horizon that assumes continued data-center demand and margin improvement without needing AMD to displace Nvidia outright…